Latest filing published 16 Mar 2023 for Allogene Therapeutics, Inc., €125k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Veer Bhavnagri (board member) discloses dealings in Allogene Therapeutics, Inc. to SEC (Form 4). In total, 12 filings cover trades dated from 17 May 2021 to 14 March 2023.
Sales make up the whole of the open-market record (4 sales, €140k). Besides market trades, the filings include 2 share grants and 6 option exercises. In 2023 alone, the filings show no purchases and 2 sales.
The record was last updated on 16 March 2023 with a share grant (€125k) in Allogene Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations